Impact of Neurodegenerative Diseases on Drug Binding to Brain Tissues: From Animal Models to Human Samples
Ana Ugarte, David Corbacho, María S Aymerich, Ana García-Osta, Mar Cuadrado-Tejedor, Julen Oyarzabal
Drug efficacy in the central nervous system (CNS) requires an additional step after crossing the blood-brain barrier. Therapeutic agents must reach their targets in the brain to modulate them; thus, the free drug concentration hypothesis is a key parameter for in vivo pharmacology.
Here, we report the impact of neurodegeneration (Alzheimer's disease (AD) and Parkinson's disease (PD) compared with healthy controls) on the binding of 10 known drugs to postmortem brain tissues from animal models and humans. Unbound drug fractions, for some drugs, are significantly different between healthy and injured brain tissues (AD or PD). In addition, drugs binding to brain tissues from AD and PD animal models do not always recapitulate their binding to the corresponding human injured brain tissues. These results reveal potentially relevant implications for CNS drug discovery.
CITATION Neurotherapeutics. 2018 Jul;15(3):742-750. doi: 10.1007/s13311-018-0624-5.